- Palisade Bio ( NASDAQ: PALI ) said on Monday it had launched its new corporate website, palisadebio.com.
- The company also reiterated its commitment to develop therapeutics that protect intestinal barrier health.
- Its lead product candidate, LB1148, is an oral liquid formulation of the well-characterized digestive enzyme inhibitor, tranexamic acid, with potential to both reduce abdominal adhesions and help restore bowel function following surgery.
- The company has begun screening first patient in a Phase 3 study testing its drug, LB1148, to help return bowel function in adult patients undergoing gastrointestinal surgery.
- ( PALI ) stock rose 3.5% before the bell.
For further details see:
Palisade Bio launches new corporate website